Hospices civils de Lyon, pôle de santé publique, Lyon, 69003, France; University Lyon, University Claude Bernard Lyon 1, HESPER EA 7425, 69008 Lyon, France.
Division of Health Sciences, Warwick medical school, University of Warwick, Gibbet Hill road, CV47AL Coventry, England, UK; Hospices Civils de Lyon, UMR-CNRS 5510, MATEIS, 69500 Bron, France.
Rev Neurol (Paris). 2020 Mar;176(3):180-188. doi: 10.1016/j.neurol.2019.06.007. Epub 2019 Sep 13.
To determine the cost-effectiveness of stent retriever thrombectomy (SRT) added to standard of care (SOC) in large vessel occlusion (LVO) strokes, adopting the French societal perspective given the lack of published studies with such perspective.
We developed an hybrid model (decision tree until one year post-stroke followed by a Markov model from one year onward). The time horizon was 20 years. We calculated transition probabilities across the modified Rankin Scale (mRS) based on a published meta-analysis. The main outcome measure was quality adjusted life-years (QALYs) gained. Resources and input costs were derived from a literature search. We calculated the incremental cost-effectiveness ratio (ICER) expressed as cost/QALY. We used 1-way deterministic and probabilistic sensitivity analysis (PSA) to evaluate the model uncertainty.
In the base-case, adding SRT to SOC resulted in increased effectiveness of 0.73 QALY while total costs were reduced by 3,874€ (ICER of -5,400€/QALY). In the scenario analysis adopting the French healthcare system perspective, the ICER was 4,901€/QALY. Parameters the most influential were the relative risks of SRT over SOC for 90-days mortality and for 90-days mRS 0-2, and the time horizon. PSA showed the 95% confidence interval of the ICER was -21,324 to 4,591€/QALY, with SRT having 85.5% chance to be dominant and 100% to be cost-effective at a threshold of 50,000€/QALY.
SRT was dominant from a French societal perspective, from 9 years post-stroke onwards. Cost-effectiveness of SRT added to SOC becomes undisputable with evidences from payer and societal viewpoints.
鉴于缺乏具有法国社会视角的相关研究,本研究旨在从法国社会视角出发,确定支架取栓术(SRT)联合标准治疗(SOC)在治疗大血管闭塞(LVO)卒中中的成本效益。
我们建立了一个混合模型(决策树直至卒中后 1 年,然后从 1 年开始使用马尔可夫模型)。时间范围为 20 年。我们根据已发表的荟萃分析计算了改良 Rankin 量表(mRS)的转移概率。主要结果是获得的质量调整生命年(QALYs)。资源和投入成本来自文献检索。我们计算了增量成本效益比(ICER),表示为每 QALY 的成本。我们使用单因素确定性和概率敏感性分析(PSA)来评估模型的不确定性。
在基础案例中,SRT 联合 SOC 可提高 0.73 个 QALY 的效果,同时降低 3874 欧元的总成本(ICER 为-5400 欧元/QALY)。在采用法国医疗保健系统视角的情景分析中,ICER 为 4901 欧元/QALY。影响最大的参数是 SRT 相对于 SOC 的 90 天死亡率和 90 天 mRS 0-2 的相对风险,以及时间范围。PSA 显示,ICER 的 95%置信区间为-21324 至 4591 欧元/QALY,SRT 有 85.5%的可能性占据优势,且在 50000 欧元/QALY 的阈值下有 100%的可能性具有成本效益。
从法国社会的角度来看,SRT 从卒中后 9 年开始就具有优势。从支付者和社会角度来看,SRT 联合 SOC 的成本效益变得无可争议。